|
|
|
|
| Meet Coriolis Pharma at CPHI Worldwide in Milan to discuss in silico services, formulation development, GMP stability studies, release testing, and product characterization. Click here to learn more |
|
|
|
|
| An Insider's View On CDMO Services For Biologics | Q&A | Thermo Fisher Scientific | Maider Parikh, VP of Commercial Operations, reveals how top biopharma teams are tackling timeline pressure, regulatory complexity, and supply chain risk. Access the full Q&A to benchmark your approach. |
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | "I should have known," writes Chief Editor Louis Garguilo, "It takes an accomplished biologist to most effectively describe the significance of artificial intelligence in our outsourcing industry and how to put it to practical use." That professional is Damiano Dragone, Founder & Principal Advisor, Dragone Consulting, who built a career across pharmaceutical quality and data-driven quality environments within the biopharmaceutical industry, and was an early proponent of the promise of AI in development and manufacturing processes and facilities. | |
|
|
CDMO Winners And Losers: The Industry Shifts Shaping Outsourcing | By Outsourced Pharma | Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| When Unexpected Particles Threaten Your Biologic | Webinar | KBI Biopharma | Particle contamination risks biologic safety. Advanced tools like Raman and SEM-EDS identify root causes fast to support robust, regulator-ready strategies that protect product quality. |
|
|
|
| Super Short Activated CAR-T Process | White Paper | Resilience | Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs. |
|
|
|
|
|
|
|
| What Does a Friendly CDMO Expert Look Like? | Article | AGC Biologics | Transparent, collaborative outsourcing reduces supply chain risk and protects IP. Open communication and proactive problem-solving keep development on track and speed commercialization. |
|
|
|
|
|
|
|
|
| Smarter Lead Selection and Faster Representative Material for Early CMC Studies | Early CMC decisions have lasting implications for biologic development programs, influencing candidate selection, development timelines, and overall risk. Join us to explore emerging approaches to cell line development and early material generation that may help teams assess biologic candidates sooner, gain more representative data earlier in development, and make informed decisions that support efficient progression toward IND-enabling studies and clinical milestones. Learn more. |
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
